HLS Therapeutics (HLS Therapeutics) 3-Year EBITDA Growth Rate : -17.00% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics 3-Year EBITDA Growth Rate?

HLS Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was $0.14.

During the past 12 months, HLS Therapeutics's average EBITDA Per Share Growth Rate was -28.90% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -17.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -10.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of HLS Therapeutics was 182.80% per year. The lowest was -40.90% per year. And the median was -2.95% per year.

Competitive Comparison of HLS Therapeutics's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HLS Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's 3-Year EBITDA Growth Rate falls into.

HLS Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

HLS Therapeutics (OTCPK:HLTRF) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

HLS Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

HLS Therapeutics (HLS Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

HLS:Canada

Address

10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2

Website

https://www.hlstherapeutics.com

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

HLS Therapeutics (HLS Therapeutics) Headlines

From GuruFocus

Automodular Corp. (TSX:AM) - Strong Buy

By Elliot Luchansky, CFA Elliot Luchansky, CFA • 03-21-2013